Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg
Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on
room air (if earlier than 2 weeks).